Fibroblast growth factor 23 (FGF 23) is mainly produced in the bone and, upon secretion,
forms a complex with a FGF receptor and coreceptor αKlotho. FGF 23 can exert several …

Fibroblast growth factor 23 (FGF23) plays a key role in the complex network between the
bones and other organs. Initially, it was thought that FGF23 exclusively regulated phosphate …

Patients with chronic kidney disease (CKD) are prone to developing cardiac hypertrophy
and fibrosis, which is associated with increased fibroblast growth factor 23 (FGF23) serum …

Background Cardiovascular fibrosis is a major contributor to cardiovascular disease, the
primary cause of death in patients with chronic kidney disease (CKD). We previously …

High fibroblast growth factor 23 (FGF23) concentrations are a strong predictor of atrial
fibrillation (AF), but researchers have not clearly determined the mechanism by which …

Valvular heart calcification is common in patients with chronic kidney disease (CKD),
especially in those receiving hemodialysis therapy, and it is associated with poor prognosis …

BACKGROUND In uremic animals, vitamin D receptor (VDR) agonists like paricalcitol (Pc)
attenuate cardiac hypertrophy, but this effect has not been replicated consistently in humans …

Introduction: This study was conducted to ensure the correlation between fibroblast growth
factor 23 (FGF23) and death and cardiovascular events in hemodialysis patients. Methods …

Background Fibroblast growth factor 23 (FGF23) is known to cause left ventricular
hypertrophy (LVH), but controversy exists concerning its effect in dialysis. This study …

Background Recent studies suggest that the phosphaturic hormone fibroblast growth factor
23 (FGF23) is involved in regulation of renal sodium excretion and blood pressure. There is …